<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id>
<journal-title>Frontiers in Cell and Developmental Biology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell Dev. Biol.</abbrev-journal-title>
<issn pub-type="epub">2296-634X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">737599</article-id>
<article-id pub-id-type="doi">10.3389/fcell.2021.737599</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Cell and Developmental Biology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Hsa_circ_0000652 Aggravates Inflammation by Activation of Macrophages and Enhancement of OX40/OX40L Interaction in Ankylosing Spondylitis</article-title>
<alt-title alt-title-type="left-running-head">Song et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Pro-Inflammatory circRNA in Ankylosing Spondylitis</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Song</surname>
<given-names>Minkai</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1550843/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Jiawen</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1460345/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yan</surname>
<given-names>Tao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bi</surname>
<given-names>Enguang</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1248447/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>An</surname>
<given-names>Taixue</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Xiangyu</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Weizhou</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Ting</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Zishuo</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shi</surname>
<given-names>Zhanjun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhang</surname>
<given-names>Chao</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/371134/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Xiao</surname>
<given-names>Jun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1394818/overview"/>
</contrib>
</contrib-group>
<aff id="aff1">
<label>
<sup>1</sup>
</label>Division of Orthopaedic Surgery, Department of Orthopaedics, NanFang Hospital, Southern Medical University, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<label>
<sup>2</sup>
</label>Division of Spinal Surgery, Department of Orthopaedics, NanFang Hospital, Southern Medical University, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<label>
<sup>3</sup>
</label>Department of Biochemistry and Molecular Biology, School of Basic Medical Science, Guangdong Provincial Key Laboratory of Single Cell Technology and Application, Southern Medical University, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<label>
<sup>4</sup>
</label>Department of Laboratory Medicine, NanFang Hospital, Southern Medical University, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff5">
<label>
<sup>5</sup>
</label>Department of Endocrinology and Metabolism, NanFang Hospital, Southern Medical University, <addr-line>Guangzhou</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/684281/overview">Benjamin Gantenbein</ext-link>, University of Bern, Switzerland</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1189148/overview">Ankan Gupta</ext-link>, Medical College of Wisconsin, United&#x20;States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/502459/overview">Pradeep Chaluvally Raghavan</ext-link>, Medical College of Wisconsin, United&#x20;States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Chao Zhang, <email>zhangchao1558@126.com</email>; Jun Xiao, <email>xiaojun@smu.edu.cn</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work and share first authorship.</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Molecular and Cellular Pathology, a section of the journal Frontiers in Cell and Developmental Biology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>16</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>9</volume>
<elocation-id>737599</elocation-id>
<history>
<date date-type="received">
<day>07</day>
<month>07</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>11</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Song, Gao, Yan, Bi, An, Wang, Jiang, Wang, Chen, Shi, Zhang and Xiao.</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Song, Gao, Yan, Bi, An, Wang, Jiang, Wang, Chen, Shi, Zhang and Xiao</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Circular RNAs (circRNAs) have emerged as important roles in various inflammatory processes of rheumatic diseases. However, their expression profiles and influences in the pathogenesis of ankylosing spondylitis (AS) remain unclear. In this study, we revealed the differential expression profiles of circRNAs in peripheral blood mononuclear cells (PBMCs) in AS by circRNA sequencing. We screened the differentially expressed circRNAs in AS and verified that hsa_circ_0000652 was upregulated and had potential to be a biomarker of progression. Functionally, hsa_circ_0000652 promoted proliferation and cytokine production in macrophages and inhibited apoptosis. Through dual-luciferase assays and RNA pull-down assays, we demonstrated that hsa_circ_0000652 acted as a competing endogenous RNA (ceRNA) by binding with hsa-miR-1179 and regulated OX40L, which is characterized as a co-stimulatory molecule and found to be upregulated in AS patients. As a result, hsa_circ_0000652 aggravated the inflammation in the coculture system containing CD4<sup>&#x2b;</sup> T&#x20;cells and macrophages via OX40/OX40L interaction. Our findings suggest that hsa_circ_0000652 was upregulated in AS patients and may serve as a pro-inflammatory factor in macrophages and a positive regulator of OX40/OX40L by sponging hsa-miR-1179.</p>
</abstract>
<kwd-group>
<kwd>circular RNA</kwd>
<kwd>competing endogenous RNA</kwd>
<kwd>ankylosing spondylitis</kwd>
<kwd>macrophage activation</kwd>
<kwd>co-stimulatory molecules</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Ankylosing spondylitis (AS) is one of the most common rheumatic diseases that cause general inflammation and irreversible arthritis involving the sacroiliac joints, hips, knees, and spinal joints (<xref ref-type="bibr" rid="B33">Taurog et&#x20;al., 2016</xref>). Due to the poor understanding of pathogenesis in AS, there is still a lack of disease-specific molecular targets for diagnosis and treatment (<xref ref-type="bibr" rid="B34">Ward et&#x20;al., 2019</xref>). Abnormal activation of immune cells is recognized as one of the leading causes in AS, but the underlying mechanisms and molecular regulators of AS disease have not been fully investigated (<xref ref-type="bibr" rid="B21">Menegatti et&#x20;al., 2020</xref>). Consequently, there remains a need for detailed clarification of the molecular mechanism in inflammation progression of&#x20;AS.</p>
<p>Extensive studies revealed that macrophages act as inflammatory mediators in many rheumatic diseases, including systemic lupus erythematosus (SLE) (<xref ref-type="bibr" rid="B22">Morel, 2017</xref>), rheumatoid arthritis (RA) (<xref ref-type="bibr" rid="B32">Tardito et&#x20;al., 2019</xref>), and AS (<xref ref-type="bibr" rid="B25">Ranganathan et&#x20;al., 2017a</xref>). Typically, macrophages are classified as pro-inflammatory macrophages (known as M1) and anti-inflammatory macrophages (known as M2). M1 macrophages, recognized as activated macrophages, which are common features in AS, are involved in bone formation (<xref ref-type="bibr" rid="B10">Horwood, 2016</xref>), cytokine production (<xref ref-type="bibr" rid="B27">Shapouri-Moghaddam et&#x20;al., 2018</xref>), and T-cell activation (<xref ref-type="bibr" rid="B7">Guerriero, 2019</xref>). Therefore, it is necessary to further determine the mechanisms of macrophage activation in&#x20;AS.</p>
<p>Circular RNA (circRNA) is well known because of its covalently looped structure by ligating the 3&#x2032; and 5&#x2032; terminals at the junction point (<xref ref-type="bibr" rid="B24">Pasman et&#x20;al., 1996</xref>; <xref ref-type="bibr" rid="B19">Li X. et&#x20;al., 2018</xref>). A massive number of studies showed that circRNAs are differentially expressed and functioned in various rheumatic and inflammatory diseases such as osteoarthritis (OA) (<xref ref-type="bibr" rid="B28">Shen et&#x20;al., 2019</xref>), SLE (<xref ref-type="bibr" rid="B18">Li L.-J.&#x20;et&#x20;al., 2018</xref>), and RA (<xref ref-type="bibr" rid="B37">Yang et&#x20;al., 2020</xref>). As a competing endogenous RNA (ceRNA), circRNA can act as a sponge for miRNA and regulate miRNA-related biological processes (<xref ref-type="bibr" rid="B20">Memczak et&#x20;al., 2013</xref>). Unfortunately, the expression profiles and underlying ceRNA mechanisms of circRNAs in AS are rarely reported.</p>
<p>Accumulating data suggest that co-stimulatory molecules are critical in modulating the interactions of immune cells (<xref ref-type="bibr" rid="B4">Croft and Siegel, 2017</xref>; <xref ref-type="bibr" rid="B9">He et&#x20;al., 2019</xref>). Among them, the OX40/OX40L axis is essential for CD4<sup>&#x2b;</sup> T-cell activation, and targeted therapy against OX40/OX40L is on a perspective way (<xref ref-type="bibr" rid="B36">Webb et&#x20;al., 2016</xref>; <xref ref-type="bibr" rid="B6">Fu et&#x20;al., 2020</xref>). Activated CD4<sup>&#x2b;</sup> T&#x20;cells are the main effector cells in synovitis and enthesitis, which eventually result in inevitable damage of bones and joints in AS patients (<xref ref-type="bibr" rid="B12">Kidd et&#x20;al., 1989</xref>; <xref ref-type="bibr" rid="B35">Watad et&#x20;al., 2020</xref>). Basically, after the ligation of OX40/OX40L, both NF-kappa B and Akt/PI3K pathways are activated, leading to prolonged survival and augmented cytokine secretion (<xref ref-type="bibr" rid="B31">Song et&#x20;al., 2004</xref>; <xref ref-type="bibr" rid="B3">Croft, 2010</xref>; <xref ref-type="bibr" rid="B23">Oh and Ghosh, 2013</xref>). Jacquemin et&#x20;al. discovered that the OX40/OX40L axis downregulated Foxp3 expression in T&#x20;cells and impaired the anti-inflammatory effect of regulatory T&#x20;cells (Tregs) in SLE (<xref ref-type="bibr" rid="B11">Jacquemin et&#x20;al., 2018</xref>). Despite the functions of the OX40/OX40L axis being clarified in many autoimmune diseases, the profiles of the OX40/OX40L axis in AS have not yet been reported.</p>
<p>In this study, we obtained a circRNA sequence to explore the differentially expressed circRNAs in peripheral blood mononuclear cells (PBMCs) from AS patients and identified a circRNA hsa_circ_0000652, which is upregulated in AS and correlated with disease activity. Subsequent assays revealed the role of hsa_circ_0000652 in macrophage activation and found that it could indirectly regulate OX40L expression by sponging hsa-miR-1179. We also discovered the OX40L<sup>high</sup> cell population in AS patients. Coculture assay further revealed the enhanced OX40/OX40L interaction between CD4<sup>&#x2b;</sup> T&#x20;cells and hsa_circ_0000652&#x2013;expressing macrophages. Our findings suggested that hsa_circ_0000652 played a pro-inflammatory role in the inflammation of AS via macrophage activation and regulation of hsa-miR-1179/OX40L.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Human Samples and Ethical Approval</title>
<p>PBMCs used in this study were taken from 76 patients diagnosed with AS according to the modified New York 1984 criteria for AS and 40 healthy controls at NanFang Hospital of Southern Medical University, Guangzhou, China. Informed consents were obtained from patients before sample collection. The study was approved by the Medical Ethics Committee of NanFang Hospital of Southern Medical University. The collected PBMCs were isolated by using a lymphocyte separation medium (Solarbio, Beijing, China), following the manufacturer&#x2019;s protocol for RNA extraction.</p>
</sec>
<sec id="s2-2">
<title>CircRNA Sequencing</title>
<p>PBMCs from three recruited AS patients and three healthy donors were separated and used for high-throughput circRNA sequencing by Geneseed Biotech Co., Ltd. (Guangzhou, China). In brief, total RNA was extracted and purified using a Magen Hipure Total RNA Mini Kit (Magen, Guangzhou, China). After the construction of RNA sequencing libraries, a Qubit 3.0 fluorometer (Invitrogen, CA, United&#x20;States) was used for quality control. Then the PE150 mode of HiSeq X10 (Illumina Inc., CA, United&#x20;States) was used for sequencing. Differentially expressed circRNAs were screened, with a fold-change &#x3e;1.5 and <italic>p</italic>&#x20;&#x3c;&#x20;0.05.</p>
</sec>
<sec id="s2-3">
<title>Cell Culture, Differentiation, and Transfection</title>
<p>The human THP-1 and Jurkat T-cell lines were purchased from iCell Bioscience (Shanghai, China). THP-1 and Jurkat T&#x20;cells were maintained in the RPMI-1640 medium (Gibco, MD, United&#x20;States) with 15% fetal bovine serum (FBS, Gibco, MD, United&#x20;States) and 1% penicillin&#x2013;streptomycin solution (Gibco, MD, United&#x20;States) in a humidified atmosphere with 5% CO<sub>2</sub> at 37&#xb0;C. The culture medium for THP-1 was supplemented with additional 50&#xa0;&#x3bc;M of &#x3b2;-mercaptoethanol (Solarbio, Beijing, China). The THP1 cells were treated with 50&#xa0;ng/ml phorbol 12-myristate 13-acetate (PMA, Solarbio, Beijing, China) for 24&#xa0;h to induce THP1-derived M0 macrophages. For further differentiation of M1 macrophages, THP1-derived M0 macrophages were treated with 100&#xa0;ng/ml lipopolysaccharides (LPS, Solarbio, Beijing, China) for 48&#xa0;h.</p>
<p>The pLV-cir-cmv-mcs-EF1a-copGFP-puro plasmid used for lentivirus-mediated overexpression of hsa_circ_0000652 was obtained from Kidan Bioscience (Guangzhou, China). The pLKO.1-U6-EF1a-copGFP-T2A-puro plasmid cloned with short hairpin sequences&#x2013;targeted hsa_circ_0000652 was purchased from IGE Biotechnology (Guangzhou, China) (<xref ref-type="sec" rid="s9">Supplementary Table S2</xref>). The plasmid for overexpression or knockdown of hsa_circ_0000652 was co-transfected with pSPAX2 and pMD2.G into 293&#xa0;T&#x20;cells, respectively. The supernatant was collected and filtered after 48&#xa0;h. THP-1 cells were cultured with the viral supernatant and supplemented with 5&#xa0;&#x3bc;g/ml polybrene (Beyotime, Beijing, China). After 48 h, the cells were collected and re-seeded in a complete growth medium. To generate stably expressed cell lines, puromycin was then added to the culture medium for 7&#xa0;days at the concentration of 1, 2, and 4&#xa0;ug/ml in sequence. For miRNA transfection, mimics of hsa-miR-1179 and the control purchased from GeneCopoeia (Guangzhou, China) were transfected by Lipofectamine 3000 (Invitrogen, CA, United&#x20;States).</p>
<p>For the coculture system, the stably expressed THP-1 cells were first seeded to 35-mm wells at the density of 2&#xd7;10<sup>5</sup> cells per well and differentiated to M1 macrophages as mentioned above. Jurkat T&#x20;cells were then collected and added to each group of the macrophages at the density of 3.5&#xd7;10<sup>5</sup> cells per well for 24&#xa0;h. To analyze the function of T&#x20;cells, the suspension of the coculture system containing T&#x20;cells was collected, washed with PBS, and added to new wells with a fresh complete growth medium. After a 24-h culture, the T&#x20;cells were collected for RNA extraction and flow cytometry, while the supernatants were collected for cytokine measurement.</p>
</sec>
<sec id="s2-4">
<title>RNA and Genomic DNA Extraction and Quantitative Real-Time PCR (qRT-PCR)</title>
<p>Total RNA from PBMCs and cultured cells was extracted using TRIzol reagent (Life Technologies, CA, United&#x20;States) according to the manufacturer&#x2019;s manuals. The RNA from the nucleus and cytoplasm was extracted using a PARIS kit (Life Technologies, CA, United&#x20;States). The gDNA was extracted using a SteadyPure Universal Genomic DNA Extraction Kit (Accurate Biology, Hunan, China). RNA for mRNA and circRNA analysis was reverse-transcribed with Evo M-MLV RT Premix (Accurate Biology, Hunan, China) and used for qRT-PCR with Hieff qPCR SYBR Green Master Mix (Yeasen Biotechnology, Shanghai, China). RNA for miRNA analysis was reverse-transcribed and used for qRT-PCR using the an miDETECT A Track miRNA qRT-PCR Starter Kit (RiboBio, Guangzhou, China). The primers used for qRT-PCR are shown in <xref ref-type="sec" rid="s9">Supplementary Table S1</xref>. Quantification of relative gene expression levels was calculated by using the 2<sup>&#x2212;&#x394;&#x394;CT</sup> method with normalization using <italic>U6</italic> or <italic>&#x3b2;-actin</italic> as endogenous controls. The assay was performed in triplicate.</p>
</sec>
<sec id="s2-5">
<title>RNase R Treatment</title>
<p>Total RNA extracted from THP-1&#x2013;derived macrophages was incubated with or without RNase R (3&#xa0;U/mg, Lucigen, WI, United&#x20;States) for 30&#xa0;min at 37&#xb0;C. The treated RNA was then reverse-transcribed with Evo M-MLV RT Premix (Accurate Biology, Hunan, China). qRT-PCR of hsa_circ_0000652 and its linear host gene <italic>IQGAP1</italic> was conducted as described before.</p>
</sec>
<sec id="s2-6">
<title>Fluorescence <italic>In Situ</italic> Hybridization (FISH)</title>
<p>The 6-FAM&#x2013;labeled probe for hsa_circ_0000652&#x20;back-splice sequence and cy5-labeled probe for hsa-miR-1179 were synthesized by BersinBio (Guangzhou, China) (<xref ref-type="sec" rid="s9">Supplementary Table S2</xref>). The circRNA FISH kit (BersinBio, Guangzhou, China) was then used for the next process. In brief, the probes were added to THP-1&#x2013; derived macrophages permeabilized with 0.5% Triton X-100 and incubated in the hybridization buffer at 37&#xb0;C overnight. After washing, the nuclei were stained with DAPI. The images captured by laser confocal microscopy were used to analyze the localization of hsa_circ_0000652 and hsa-miR-1179 in cells. Pearson&#x2019;s correlation coefficient was used to quantify the co-localization.</p>
</sec>
<sec id="s2-7">
<title>Cell Proliferation Assay</title>
<p>In the cell counting kit-8 (CCK-8, Beyotime, Beijing, China) assay, stably expressed THP-1 cells were seeded in 96-well plates with a density of 2&#xd7;10<sup>3</sup> per well and added with 10&#xa0;&#x3bc;L of the CCK-8 reagent for 2&#xa0;h at 0, 24, 48, 72, and 96&#xa0;h. The optical density of CCK-8 at 450&#xa0;nm was then measured using an Infinite 200 PRO microplate reader (TECAN, Switzerland). Results of each time point were analyzed with five independent replicates. In 5-ethynyl-2&#x2032;-deoxyuridine (EdU) assay, stably expressed THP-1 cells were seeded in 12-well plates and derived to M0 macrophages as previously described. Then the cells were stained using the BeyoClick EdU-555 kit (Beyotime, Beijing, China) according to the manufacturer&#x2019;s instructions. The nuclei of all the cells were stained with Hoechst 33,342. Images from three random scopes of each group captured by a fluorescence microscope were analyzed by ImageJ software (Bethesda, MD, United&#x20;States).</p>
</sec>
<sec id="s2-8">
<title>Cell Apoptosis Assay</title>
<p>The cell apoptosis assay for stably expressed THP-1 cells was conducted using the Annexin V-APC/PI Apoptosis Detection Kit (KeyGEN, Jiangsu, China) following the manufacturer&#x2019;s instruction. In brief, the cells were collected and washed with 1&#xd7; phosphate-buffered saline (PBS, Solarbio, Beijing, China), added with 3% FBS three times, and then incubated with Annexin V-APC/PI for 15&#xa0;min. In the CytoFLEX flow cytometer (Beckman Coulter, CA, United&#x20;States), the FL3 channel was used for detection of PI and FL4 channel was used to detect Annexin V-APC. The results were analyzed by CytExpert software (Beckman Coulter, CA, United&#x20;States). The experiments were performed at least in triplicate.</p>
</sec>
<sec id="s2-9">
<title>Flow Cytometry</title>
<p>To identify the expression patterns of OX40/OX40L on CD3<sup>&#x2b;</sup>CD4<sup>&#x2b;</sup>, CD3<sup>&#x2b;</sup>CD4<sup>&#x2212;</sup>, CD3<sup>&#x2212;</sup>CD14<sup>&#x2b;</sup>, CD3<sup>&#x2212;</sup>CD19<sup>&#x2b;</sup>, CD3<sup>&#x2212;</sup>CD56<sup>&#x2b;</sup>, and CD3<sup>&#x2212;</sup>CD83<sup>&#x2b;</sup>, PBMCs from recruited AS patients and healthy controls were collected for flow cytometry. The cells from one sample were separated to two tubes and washed with 1&#xd7; phosphate buffer saline (PBS, Solarbio, Beijing, China) and added with 3% FBS three times. Then anti&#x2013;CD3-PerCP 5.5, anti&#x2013;CD4-PE Cy7, anti&#x2013;CD14-FITC, anti&#x2013;OX40-APC, and anti&#x2013;OX40L-PE were added into the first tube of each sample. Anti&#x2013;CD3-PerCP 5.5, anti&#x2013;CD56-PE Cy7, anti&#x2013;CD83-FITC, anti&#x2013;CD19-APC Cy7, anti&#x2013;OX40-APC, and anti&#x2013;OX40L-PE were added into the second tube of each sample. Stably expressed THP-1 cells and Jurkat T&#x20;cells from the coculture system were also stained with anti&#x2013;OX40L-PE or anti&#x2013;OX40-APC. All antibodies mentioned above were obtained from BioLegend (CA, United&#x20;States). After incubation on ice for 30&#xa0;min, the samples were washed and examined by using a CytoFLEX flow cytometer (Beckman Coulter, CA, United&#x20;States). The data were analyzed using FlowJo software (Tree Star, OR, United&#x20;States).</p>
</sec>
<sec id="s2-10">
<title>Enzyme-Linked Immunosorbent Assay (ELISA)</title>
<p>The secretion levels of TNF-&#x3b1;, IL-6, and IL-23 in the supernatants of stably expressed THP-1&#x2013;derived macrophages and the coculture system were measured by ELISA kits (MEIMIAN, Jiangsu, China) following the manufacturer&#x2019;s instruction. The absorbance values at the wavelength of 450&#xa0;nm were then measured using an Infinite 200 PRO microplate reader (TECAN, Switzerland). Data were expressed as mean&#x20;&#xb1; standard deviation (SD) of three separate experiments.</p>
</sec>
<sec id="s2-11">
<title>Dual-Luciferase Reporter Assay</title>
<p>The wild-type (WT) and mutant (Mut) sequences of the predicted binding sites of hsa-miR-1179 in hsa_circ_0000652 were first cloned to the pEZX-MT06 luciferase vector (GeneCopoeia, Guangzhou, China) (<xref ref-type="sec" rid="s9">Supplementary Table S2</xref>). The empty vector was used as a negative control (NC). Then the vectors were co-transfected with the hsa-miR-1179 mimic or its negative control into 293&#xa0;T&#x20;cells using Lipofectamine 3000 (Invitrogen, CA, United&#x20;States), respectively. Activity of Renilla luciferase and firefly luciferase was determined at 48&#xa0;h after transfection using the Luc-pair Duo-Luciferase HS assay kit (GeneCopoeia, Guangzhou, China).</p>
</sec>
<sec id="s2-12">
<title>RNA Pull-Down Assay</title>
<p>Biotin-labeled probes for hsa_circ_0000652, hsa-miR-1179, and corresponding negative control were designed and synthesized by RiboBio (Guangzhou, China) (<xref ref-type="sec" rid="s9">Supplementary Table S2</xref>). The RNA pull-down kit (BersinBio, Guangzhou, China) was used for the assay according to the manufacturer&#x2019;s protocol. In brief, the biotin-labeled probes were first conjugated with magnetic beads for 30&#xa0;min. Then the cells were cross-linked with formaldehyde and lysed and incubated with magnetic beads at 4&#xb0;C overnight. After treatment with proteinase K, the samples were added with TRIzol reagent and used for RNA extraction as previously described. QRT-PCR was used to analyze the expression of hsa-miR-1179, hsa_circ_0000652, and OX40L mRNA, respectively.</p>
</sec>
<sec id="s2-13">
<title>Statistical Analysis</title>
<p>Each experiment was conducted with at least three independent replicates. The quantitative data with Gaussian distribution were presented as mean&#x20;&#xb1; SD, and the data with non-Gaussian distribution were presented as median with quartile. Student&#x2019;s <italic>t-</italic>test, Welch&#x2019;s <italic>t</italic>-test, or the Mann&#x2013;Whitney <italic>U</italic> test was used for comparison of the two groups depending on distribution and homoscedasticity of data. Two-way ANOVA was used for multi-factorial comparisons. Pearson&#x2019;s correlation was used to identify the correlation. All tests were performed and calculated using GraphPad Prism 8 (GraphPad Software, CA, United&#x20;States). A <italic>p</italic> value &#x3c;0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Characteristics of Differentially Expressed circRNAs in AS</title>
<p>To explore the differentially expressed circRNAs in AS, three samples of PBMCs from AS patients with high disease activity (ASDAS<sub>CRP</sub> score &#x3e;2.1) and three samples from healthy controls were analyzed by high-throughput circRNA sequencing. With the threshold of fold-change &#x3e; 1.5 and <italic>p</italic> value &#x3c;0.05, we identified 65 upregulated and 40 downregulated circRNAs in AS patients compared to healthy controls (<xref ref-type="fig" rid="F1">Figures 1A,B</xref>). Then we further analyzed chromosome distribution of differentially expressed circRNAs and have presented them in <xref ref-type="fig" rid="F1">Figure&#x20;1C</xref>. Reactome enrichment was used to identify the biological pathways, indicating that multiple inflammatory pathways were involved in AS (<xref ref-type="fig" rid="F1">Figure&#x20;1D</xref>). Accordingly, these results showed that the expression profiles of multiple circRNAs varied in AS patients and healthy controls and may be correlated with inflammatory pathways.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Characteristics of differentially expressed circRNAs in PBMCs from AS patients. <bold>(A)</bold> Heatmap of all differentially expressed circRNAs in PBMCs from AS patients; <bold>(B)</bold> volcano scatter plot of differentially expressed circRNAs in PBMCs from AS patients; <bold>(C)</bold> chromosome distribution of differentially expressed circRNAs in PBMCs from AS patients; <bold>(D)</bold> reactome enrichment dot plot of the host genes of differentially expressed circRNAs in PBMCs from AS patients.</p>
</caption>
<graphic xlink:href="fcell-09-737599-g001.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>Hsa_circ_0000652 Is Upregulated in PBMCs From AS Patients and Associated With Disease Activity</title>
<p>Among the differentially expressed circRNAs, hsa_circ_0000652 was significantly upregulated in 76 AS patients compared to 40 healthy controls by qRT-PCR analysis (<xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>, <italic>p</italic>&#x20;&#x3c; 0.001). Interestingly, the expression levels of hsa_circ_0000652 in AS patients with low disease activity (AS-LDA, 1.3 &#x3c; ASDAS<sub>CRP</sub> score &#x2264;2.1) were still significantly higher than those in healthy controls and lower than those in patients with severe disease activity (AS-HDA, ASDAS<sub>CRP</sub> score &#x3e;2.1) (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>, n of HC &#x3d; 40, n of AS-LDA &#x3d; 29, and n of AS-HDA &#x3d; 47, <italic>p</italic>&#x20;&#x3c; 0.001 for AS-LDA vs. HC and AS-HDA vs AS-LDA). Correlation analysis suggested that the expression levels of hsa_circ_0000652 were statistically correlated with the Ankylosing Spondylitis Disease Activity Score (ASDAS<sub>CRP</sub>), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and level of C-reactive protein (<xref ref-type="fig" rid="F2">Figures 2C&#x2013;E</xref>, <italic>p</italic>&#x20;&#x3c; 0.001).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Hsa_circ_0000652 is upregulated in PBMCs from AS patients and correlated with disease activity. <bold>(A&#x2013;B)</bold> Expression of hsa_circ_0000652 in PBMCs from 76 AS patients with different disease activities and 40 healthy controls was analyzed by quantitative real-time PCR (qRT-PCR). <bold>(C&#x2013;E)</bold> Correlation analysis for the expression of hsa_circ_0000652 with the Ankylosing Spondylitis Disease Activity Score (ASDAS<sub>CRP</sub>), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and C-reactive protein (CRP) level (mg/L) of AS patients (n &#x3d; 72). <bold>(F)</bold> Schematic illustration showing the formation of hsa_circ_0000652 from its host gene <italic>IQGAP1</italic> by back-splicing. <bold>(G)</bold> Agarose gel electrophoresis of PCR amplification by divergent and convergent primers of hsa_circ_0000652 in cDNA and gDNA. <bold>(H)</bold> Back-splice junction point of hsa_circ_0000652 was identified by Sanger sequencing. <bold>(I)</bold> qRT-PCR analysis of hsa_circ_0000652 and <italic>IQGAP1</italic> and <italic>GAPDH</italic> with or without RNase R treatment (n &#x3d; 3). <bold>(J&#x2013;K)</bold> FISH assay and nuclear-cytoplasmic separation assay showed that hsa_circ_0000652 was mainly localized in the cytoplasm of the THP-1 cell line. Data in A and B are presented as median&#x20;&#xb1; quartile and data in I and H are presented as mean&#x20;&#xb1; SD. &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x003c; 0.001.</p>
</caption>
<graphic xlink:href="fcell-09-737599-g002.tif"/>
</fig>
<p>Bioinformatics analysis implicated that hsa_circ_0000652 was formed by exons 8 and 9 of its host gene <italic>IQGAP1</italic> by back-splicing (<xref ref-type="fig" rid="F2">Figure&#x20;2F</xref>). To verify the formation of hsa_circ_0000652, we performed PCR amplification and agarose gel electrophoresis for cDNA and gDNA using divergent and convergent primers. The results showed that convergent primers were amplified only in cDNA while divergent primers could be amplified in both kinds of the DNA template (<xref ref-type="fig" rid="F2">Figure&#x20;2G</xref>). Sanger sequencing of the PCR product amplified by divergent primers identified the back-splice junction point of hsa_circ_0000652 (<xref ref-type="fig" rid="F2">Figure&#x20;2H</xref>). After RNase R digestion, linear RNAs such as <italic>GAPDH</italic> and <italic>IQGAP1</italic> were degraded, but hsa_circ_0000652 was still intact due to its circular structure (<xref ref-type="fig" rid="F2">Figure&#x20;2I</xref>). Notably, FISH assay and nuclear-cytoplasmic separation, followed by qRT-PCR analysis suggested that hsa_circ_0000652 was mainly localized in the cytoplasm (<xref ref-type="fig" rid="F2">Figures 2J,K</xref>, Pearson&#x2019;s R value &#x3d; 0.59 for co-localization in FISH assay of hsa_circ_0000652 and DAPI).</p>
</sec>
<sec id="s3-3">
<title>Hsa_circ_0000652 Modulates Activation of Macrophages</title>
<p>As antigen-processing cells have important roles in AS, we hypothesized that hsa_circ_0000652 participated in mononuclear macrophage&#x2013;related inflammation. qRT-PCR showed that the expression levels of hsa_circ_0000652 and marker genes related to macrophage activation significantly increased in THP-1&#x2013;derived M0 and M1 macrophages compared to those in wild-type THP-1 (<xref ref-type="fig" rid="F3">Figure&#x20;3A</xref>, TNF-&#x3b1;: <italic>p</italic>&#x20;&#x3d; 0.0053 for M0 vs. wild-type; hsa_circ_0000652: <italic>p</italic>&#x20;&#x3d; 0.0024 for M0 vs. wild-type, <italic>p</italic>&#x20;&#x3d; 0.0022 for M0 vs. M1; others: <italic>p</italic>&#x20;&#x3c; 0.001 for M0 vs. wild-type and M1 vs. M0). To further determine the functions of hsa_circ_0000652, we constructed stably expressed THP-1 cell lines with overexpression or knockdown of hsa_circ_0000652 (<xref ref-type="fig" rid="F3">Figures 3B,C</xref>, <italic>p</italic>&#x20;&#x3c; 0.001 for LV-Vector vs. LV-circ0652; <italic>p</italic>&#x20;&#x3d; 0.0019 for LV-sh-NC vs. LV-sh-circ0652).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Hsa_circ_0000652 promotes the activation of macrophages. <bold>(A)</bold> Quantitative real-time PCR (qRT-PCR) analysis of IL-1b, IL-12, TNF-&#x3b1;, and hsa_circ_0000652 during the activation of THP-1&#x2013;derived macrophages (n &#x3d; 3); <bold>(B&#x2013;C)</bold> observation of copGFP and qRT-PCR analysis in hsa_circ_0000652 stably expressed THP-1 cell lines; <bold>(D&#x2013;G)</bold> 5-ethynyl-2&#x2032;-deoxyuridine (EdU) assay and cell counting kit-8 (CCK-8) assay after overexpression and knockdown of hsa_circ_0000652; <bold>(H&#x2013;I)</bold> Annexin V&#x2013;PI assay determined the apoptotic cell ratio of THP-1&#x2013;derived macrophages with overexpression and knockdown of hsa_circ_0000652 (n &#x3d; 3); <bold>(J&#x2013;L)</bold> ELISA of cytokine levels in the culture medium of THP-1&#x2013;derived macrophages with overexpression and knockdown of hsa_circ_0000652 (n &#x3d; 3). Data in bar plots and line plots are presented as mean&#x20;&#xb1; SD, and data in scatter plots are supplemented with line of mean. &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01; &#x2a;&#x2a;&#x2a;<italic>P</italic> &#x003c; 0.001. Each experiment was performed at least in triplicate.</p>
</caption>
<graphic xlink:href="fcell-09-737599-g003.tif"/>
</fig>
<p>Proliferation and apoptosis are closely related with the activation of macrophages. The results of EdU and CCK-8 assays illustrated that THP-1&#x2013;derived macrophages with overexpression of hsa_circ_0000652 (LV-circ0652) had a significantly higher ratio of proliferating cells than its negative controls (LV-Vector) (<xref ref-type="fig" rid="F3">Figures 3D,E</xref>, <italic>p</italic>&#x20;&#x3c; 0.001). But, the knockdown of hsa_circ_0000652 (LV-sh-circ0652) led to a restraint of proliferation compared to controls (LV-sh-NC) (<xref ref-type="fig" rid="F3">Figures 3F,G</xref>, <italic>p</italic>&#x20;&#x3c; 0.001). Flow cytometry assay demonstrated that THP-1 cells derived from macrophages with overexpression of hsa_circ_0000652 exhibited a lower ratio of apoptoptic cells than that of control cells, while knockdown of hsa_circ_0000652 significantly increased the amount of apoptoptic cells (<xref ref-type="fig" rid="F3">Figures 3H,I</xref>, <italic>p</italic>&#x20;&#x3d; 0.0013 for LV-Vector vs. LV-circ0652; <italic>p</italic>&#x20;&#x3c; 0.001 for LV-sh-NC vs. LV-sh-circ0652).</p>
<p>ELISA analysis for pro-inflammatory cytokines demonstrated that TNF-&#x3b1;, IL-6, and IL-23 in the culture medium of THP-1&#x2013;derived macrophages with overexpression of hsa_circ_0000652 were elevated compared to those of the control (<xref ref-type="fig" rid="F3">Figure&#x20;3J-L</xref>, TNF-&#x3b1; and IL-6: <italic>p</italic>&#x20;&#x3c; 0.001, IL-23: <italic>p</italic>&#x20;&#x3d; 0.0018 for LV-Vector vs. LV-circ0652). Meanwhile, knockdown of hsa_circ_0000652 ameliorated the secretion of TNF-&#x3b1;, IL-6, and IL-23 compared to that of control cells (<xref ref-type="fig" rid="F3">Figure&#x20;3J</xref>-L, TNF-&#x3b1;: <italic>p</italic>&#x20;&#x3d; 0.0058, IL-6: <italic>p</italic>&#x20;&#x3d; 0.0016, IL-23: <italic>p</italic>&#x20;&#x3d; 0.0030 for LV-sh-NC vs. LV-sh-circ0652). In summary, hsa_circ_0000652 modulated macrophage activation by regulating proliferation, apoptosis, and secretion of pro-inflammatory cytokines.</p>
</sec>
<sec id="s3-4">
<title>Hsa_circ_0000652 Serves as a Sponge of Hsa-miR-1179 to Upregulate OX40L Expression</title>
<p>To further investigate the underlying functions of hsa_circ_0000652 in macrophages, bioinformatics analysis was conducted. The results from circInteractome, TargetScan, and MiRanda platform predicted that hsa_circ_0000652 potentially served as a sponge for hsa-miR-1179, while hsa-miR-1179 could bind to 3&#x2032;-UTR of OX40L mRNA (<xref ref-type="fig" rid="F4">Figures 4A,B</xref>). Moreover, FISH assay demonstrated that hsa_circ_0000652 and hsa-miR-1179&#x20;co-localized in THP-1&#x2013;derived macrophages (<xref ref-type="fig" rid="F4">Figure&#x20;4C</xref>, Pearson&#x2019;s R value &#x3d; 0.81 for co-localization of hsa_circ_0000652 and hsa-miR-1179). Interestingly, the expression of hsa-miR-1179 was downregulated in hsa_circ_0000652 overexpressed cells but upregulated in hsa_circ_0000652 knockdown cells (<xref ref-type="fig" rid="F4">Figure&#x20;4D</xref>, <italic>p</italic>&#x20;&#x3d; 0.0178 for LV-Vector vs. LV-circ0652; <italic>p</italic>&#x20;&#x3c; 0.001 for LV-sh-NC vs. LV-sh-circ0652). Besides, hsa-miR-1179 was decreased in cells co-infected with hsa_circ_0000652 and hsa-miR-1179 compared to cells transfected with hsa-miR-1179 only (<xref ref-type="fig" rid="F4">Figure&#x20;4D</xref>, <italic>p</italic>&#x20;&#x3c; 0.001). Furthermore, the expression of hsa_circ_0000652 was found to be significantly correlated with OX40L expression in PBMCs (<xref ref-type="fig" rid="F4">Figure&#x20;4E</xref>, <italic>p</italic>&#x20;&#x3c; 0.001). Based on these results, we hypothesized that hsa_circ_0000652 could indirectly upregulate OX40L expression by blocking hsa-miR-1179.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Hsa_circ_0000652 upregulates OX40L expression by sponging hsa-miR-1179. <bold>(A&#x2013;B)</bold> Binding sites of hsa_circ_0000652 and hsa-miR-1179 and 3&#x2032; UTR of OX40L mRNA and hsa-miR-1179 predicted by circInteractome, TargetScan, and MiRanda platforms. <bold>(C)</bold> Co-localization analysis of hsa_circ_0000652 and hsa-miR-1179 in THP-1&#x2013;derived macrophages by fluorescence <italic>in situ</italic> hybridization (FISH) assay. <bold>(D)</bold> Quantitative real-time PCR (qRT-PCR) analysis of hsa-miR-1179 in hsa_circ_0000652 stably expressed THP-1 cells and THP-1 transfected with the hsa-miR-1179 mimic or negative control (n &#x3d; 3). <bold>(E)</bold> Correlation analysis for hsa_circ_0000652 and OX40L mRNA in PBMCs from AS patients and healthy controls (n &#x3d; 103). <bold>(F)</bold> Dual-luciferase assay detected the binding between hsa_circ_0000652 and hsa-miR-1179. <bold>(G)</bold> qRT-PCR analysis of hsa-miR-1179 in the immunoprecipitates of RNA immunoprecipitation (RIP) assay using probes for hsa_circ_0000652 or the negative control (n &#x3d; 3). <bold>(H)</bold> qRT-PCR analysis of hsa_circ_0000652 and OX40L mRNA in the immunoprecipitates of RIP assay using probes for hsa-miR-1179 or the negative control (n &#x3d; 3). <bold>(I)</bold> QRT-PCR analysis of OX40L in hsa_circ_0000652 stably expressed THP-1 cells and THP-1 transfected with hsa-miR-1179 mimic or the negative control (n &#x3d; 3). <bold>(J)</bold> Flow cytometry analysis of OX40L on hsa_circ_0000652 stably expressed THP-1 cells (n &#x3d; 3). Data in bar plots are presented as mean&#x20;&#xb1; SD. &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05; &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01; &#x2a;&#x2a;&#x2a;<italic>p &#x3c;</italic> 0.001.</p>
</caption>
<graphic xlink:href="fcell-09-737599-g004.tif"/>
</fig>
<p>In the dual luciferase reporter assay, the hsa-miR-1179 mimic remarkably attenuated the luciferase activity of cells co-transfected with wild-type hsa_circ_0000652 but did not change in the mutant group (<xref ref-type="fig" rid="F4">Figure&#x20;4F</xref>, <italic>p</italic>&#x20;&#x3d; 0.0081 for circ0652 WT &#x2b; hsa-miR-1179 mimic vs. circ0652 WT &#x2b; NC mimic, <italic>p</italic>&#x20;&#x3d; 0.8290 for circ0652 Mut &#x2b; hsa-miR-1179 mimic vs. circ0652 Mut &#x2b; NC mimic). In the RNA pull-down assay, qRT-PCR analysis showed that more hsa-miR-1179 were enriched by hsa_circ_0000652 probes than by control probes (<xref ref-type="fig" rid="F4">Figure&#x20;4G</xref>, <italic>p</italic>&#x20;&#x3c; 0.001 for the circ0652 probe vs. the circ-NC probe). Moreover, biotin-labeled hsa-miR-1179 probes enriched more hsa_circ_0000652 and OX40L mRNA than control probes (<xref ref-type="fig" rid="F4">Figure&#x20;4H</xref>, <italic>p</italic>&#x20;&#x3c; 0.001 for miR1179 probe vs. miR-NC probe).</p>
<p>To clarify the indirect regulation between hsa_circ_0000652 and OX40L, we performed qRT-PCR and flow cytometry of OX40L in hsa_circ_0000652 stably expressed THP-1 cells. Notably, the expression levels of OX40L mRNA were higher in cells with hsa_circ_0000652 overexpression than the control but lower in cells with hsa_circ_0000652 knockdown (<xref ref-type="fig" rid="F4">Figure&#x20;4I</xref>, <italic>p</italic>&#x20;&#x3c; 0.001 for LV-Vector vs. LV-circ0652 and LV-sh-NC vs. LV-sh-circ0652). THP-1 cells transfected with hsa-miR-1179 mimics also showed reduced OX40L mRNA expression than the control (<xref ref-type="fig" rid="F4">Figure&#x20;4I</xref>, <italic>p</italic>&#x20;&#x3d; 0.0016 for miR-1179 vs. miR-NC). Remarkably, the reduction was partially rescued in cells co-infected with hsa-miR-1179 and hsa_circ_0000652 (<xref ref-type="fig" rid="F4">Figure&#x20;4I</xref>, <italic>p</italic>&#x20;&#x3d; 0.0048 for miR-1179 vs. miR-NC). In flow cytometry analysis, the expression of OX40L was significantly greater in cells with overexpression of hsa_circ_0000652 than in controls (<xref ref-type="fig" rid="F4">Figure&#x20;4J</xref>, <italic>p</italic>&#x20;&#x3c; 0.001 for LV-Vector vs. LV-circ0652). Meanwhile, knockdown of hsa_circ_0000652 resulted in attenuated expression of OX40L than controls (<xref ref-type="fig" rid="F4">Figure&#x20;4J</xref>, <italic>p</italic>&#x20;&#x3c; 0.001 for LV-sh-NC vs. LV-sh-circ0652). Collectively, the results described above revealed that hsa_circ_0000652 upregulated the expression of OX40L by blocking hsa-miR-1179.</p>
</sec>
<sec id="s3-5">
<title>Expression Profiles of OX40L in AS</title>
<p>As the expression of OX40L was not yet reported in AS, we performed several assays on PBMCs obtained from AS patients and healthy controls. First, qRT-PCR analysis demonstrated that increased OX40L expression was seen in the AS group compared with that of the healthy controls (left of <xref ref-type="fig" rid="F5">Figure&#x20;5A</xref>, <italic>p</italic>&#x20;&#x3c; 0.001). Moreover, the expression of OX40L in AS patients with low disease activity was significantly higher than that of the healthy controls and lower than that in patients with high disease activity (right of <xref ref-type="fig" rid="F5">Figure&#x20;5A</xref>, <italic>p</italic>&#x20;&#x3c; 0.001 for AS-HDA vs. AS-LDA and AS-LDA vs. HC). Furthermore, the ASDAS score and BASDAI score of involved AS patients were found to be correlated with the expression level of OX40L (<xref ref-type="fig" rid="F5">Figures 5B,C</xref>, <italic>p</italic>&#x20;&#x3c; 0.001).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Expression profiles of OX40L in PBMCs of AS patients. <bold>(A)</bold> Quantitative real-time PCR (qRT-PCR) analysis of OX40L mRNA in PBMCs of 72 AS patients with different disease activities and 31 healthy controls. <bold>(B,C)</bold> Correlation analysis for OX40L in PBMCs with the ASDAS and BASDAI score of AS patients (n &#x3d; 72). (D). OX40L and its receptor, OX40, were tested in PBMCs of AS patients (n &#x3d; 26) and healthy controls (n &#x3d; 12) by flow cytometry. Mean fluorescence intensity (MFI) was used to analyze differentially expressed OX40/OX40L on cells marked by CD3<sup>&#x2b;</sup>CD4<sup>&#x2b;</sup>, CD3<sup>&#x2b;</sup>CD4<sup>&#x2212;</sup>, CD3<sup>&#x2212;</sup>CD14<sup>&#x2b;</sup>, CD3<sup>&#x2212;</sup>CD19<sup>&#x2b;</sup>, CD3<sup>&#x2212;</sup>CD56<sup>&#x2b;</sup>, and CD3<sup>&#x2212;</sup>CD83<sup>&#x2b;</sup>. <bold>(E,F)</bold> Cell ratios of CD3<sup>&#x2212;</sup>CD14<sup>&#x2b;</sup> cells and CD3<sup>&#x2b;</sup>CD4<sup>&#x2b;</sup> T&#x20;cells in PBMCs of AS patients (n &#x3d; 26) and healthy controls (n &#x3d; 12) were detected by flow cytometry; <bold>(G)</bold> represented illustration and MFI of OX40L on the CD3<sup>&#x2212;</sup>CD14<sup>&#x2b;</sup> cell group of PBMCs from AS patients and healthy controls followed by flow cytometry. Data in A are presented as median&#x20;&#xb1; quartile, and data in other chart plots are presented as mean&#x20;&#xb1; SD. ns: <italic>p</italic>&#x20;&#x2265; 0.05; &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01; &#x2a;&#x2a;&#x2a;<italic>p &#x3c;</italic> 0.001.</p>
</caption>
<graphic xlink:href="fcell-09-737599-g005.tif"/>
</fig>
<p>OX40L is widely expressed on multiple antigen-processing cells with various functions. To reveal the high OX40L-expressing cells, we analyzed the expression of OX40L in different cell populations of PBMCs from AS patients and healthy controls by flow cytometry and found that OX40L was mainly expressed by CD3<sup>&#x2212;</sup>CD14<sup>&#x2b;</sup> cells, while its receptor OX40 was mainly located on CD3<sup>&#x2b;</sup>CD4<sup>&#x2b;</sup> T&#x20;cells (<xref ref-type="fig" rid="F5">Figure&#x20;5D</xref>, <italic>p</italic>&#x20;&#x3c; 0.001 for OX40L on CD3<sup>&#x2212;</sup>CD14<sup>&#x2b;</sup> cells and OX40 on CD3<sup>&#x2b;</sup>CD4<sup>&#x2b;</sup> T&#x20;cells compared to other cell groups). Further analysis showed that the percentage of CD3<sup>&#x2212;</sup>CD14<sup>&#x2b;</sup> cells was remarkably higher in AS patients with high disease activity than patients with low disease activity and healthy controls (<xref ref-type="fig" rid="F5">Figure&#x20;5E</xref>, <italic>p</italic>&#x20;&#x3c; 0.001 for AS-HDA vs. AS-LDA, <italic>p</italic>&#x20;&#x3d; 0.6211 for AS &#x3d; LDA vs. HC). Nevertheless, cell ratios of CD3<sup>&#x2b;</sup>CD4<sup>&#x2b;</sup> T&#x20;cells did not differ among groups of AS patients with high or low disease activity and healthy controls (<xref ref-type="fig" rid="F5">Figure&#x20;5F</xref>, <italic>p</italic>&#x20;&#x3d; 0.7931 for AS-HDA vs. AS-LDA, <italic>p</italic>&#x20;&#x3d; 0.2911 for AS &#x3d; LDA vs. HC). Additionally, OX40L expression on CD3<sup>&#x2212;</sup>CD14<sup>&#x2b;</sup> cells was increased in AS patients, rather than healthy controls (<xref ref-type="fig" rid="F5">Figure&#x20;5G</xref>, <italic>p</italic>&#x20;&#x3d; 0.0067). Taken together, OX40L was upregulated and correlated with disease activity in AS patients and is mainly expressed on CD3<sup>&#x2212;</sup>CD14<sup>&#x2b;</sup>&#x20;cells.</p>
</sec>
<sec id="s3-6">
<title>Hsa_circ_0000652 Enhances the Interaction Between Macrophages and CD4<sup>&#x2b;</sup> T&#x20;Cells via OX40/OX40L</title>
<p>To verify the effect of OX40/OX40L interaction regulated by hsa_circ_0000652, we designed a coculture system of THP-1&#x2013;derived macrophages and Jurkat T&#x20;cells (<xref ref-type="fig" rid="F6">Figure&#x20;6A</xref>). After being cocultured with hsa_circ_0000652 stably expressed THP-1&#x2013;derived macrophages for 24&#xa0;h, T&#x20;cells were separately cultured for 24&#xa0;h and collected for the following analysis. As OX40 is the receptor of OX40L and TRAF2 is one of the most important downstream mediators of OX40/OX40L, we conducted qRT-PCR analysis of OX40 and TRAF2 in T&#x20;cells. Expression levels of both OX40 and TRAF2 were upregulated in cells cocultured with macrophages overexpressing hsa_circ_0000652 compared to controls and were rescued by co-transfecting hsa-miR-1179 (<xref ref-type="fig" rid="F6">Figure&#x20;6B</xref>, OX40: <italic>p</italic>&#x20;&#x3c; 0.001 for LV-Vector vs. LV-circ0652; <italic>p</italic>&#x20;&#x3d; 0.3525 for LV-sh-NC vs. LV-sh-circ0652; <italic>p</italic>&#x20;&#x3d; 0.0104 for miR-1179 vs. miR-1179&#x2b;LV-circ0652; TRAF2: <italic>p</italic>&#x20;&#x3c; 0.001 for LV-Vector vs. LV-circ0652; <italic>p</italic>&#x20;&#x3d; 0.100 for LV-sh-NC vs. LV-sh-circ0652; <italic>p</italic>&#x20;&#x3d; 0.0258 for miR-1179 vs. miR-1179&#x2b;LV-circ0652). However, knockdown of hsa_circ_0000652 in cells cocultured with macrophages did not show a statistically significant reduction in the expression of OX40 and TRAF2. These results were confirmed in the protein level analyzed by flow cytometry (<xref ref-type="fig" rid="F6">Figure&#x20;6C</xref>, <italic>p</italic>&#x20;&#x3c; 0.001 for LV-Vector vs. LV-circ0652 and miR-1179 vs. miR-1179&#x2b;LV-circ0652). Consistently, knockdown of hsa_circ_0000652 in macrophages resulted in restraint of OX40 expression on T&#x20;cells (<xref ref-type="fig" rid="F6">Figure&#x20;6D</xref>, <italic>p</italic>&#x20;&#x3c; 0.001 for LV-sh-NC vs. LV-sh-circ0652). ELISA assay showed that elevated levels of TNF-&#x3b1;, IL-6, and IL-23 were detected in the supernatant of T&#x20;cells cocultured with macrophages overexpressing hsa_circ_0000652 and could be rescued by hsa_miR-1179 overexpression (<xref ref-type="fig" rid="F6">Figures 6E&#x2013;G</xref>, TNF&#x3b1;: <italic>p</italic>&#x20;&#x3d; 0.0015 for LV-Vector vs. LV-circ0652, <italic>p</italic>&#x20;&#x3d; 0.024 for LV-sh-NC vs. LV-sh-circ0652; <italic>p</italic>&#x20;&#x3d; 0.0215 for miR-1179 vs. miR-1179&#x2b;LV-circ0652; IL-6 and IL-23: <italic>p</italic>&#x20;&#x3c; 0.001 for LV-Vector vs. LV-circ0652, LV-sh-NC vs. LV-sh-circ0652 and miR-1179 vs. miR-1179&#x2b;LV-circ0652). On the contrary, knockdown of hsa_circ_0000652 in macrophages exerted adverse effects by reducing levels of cytokines mentioned above. In conclusion, hsa_circ_0000652 aggravated the inflammation of macrophages and CD4<sup>&#x2b;</sup> T&#x20;cells <italic>via</italic> the hsa-miR-1179/OX40L/OX40 pathway.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Hsa_circ_0000652 regulates inflammation caused by OX40/OX40L interaction between macrophages and CD4<sup>&#x2b;</sup> T&#x20;cells. <bold>(A)</bold> Schematic illustration of macrophages and CD4<sup>&#x2b;</sup> T-cell coculture system. <bold>(B)</bold> QRT-PCR analysis of OX40 and OX40L in CD4<sup>&#x2b;</sup> T&#x20;cells after being cocultured with hsa_circ_0000652 stably expressed THP-1 cell lines with or without hsa-miR-1179 mimics (n &#x3d; 3). <bold>(C,D)</bold> Flow cytometry of OX40 in CD4<sup>&#x2b;</sup> T&#x20;cells after coculturing with hsa_circ_0000652 stably expressed THP-1 cell lines with or without hsa-miR-1179 mimics (n &#x3d; 3). <bold>(E&#x2013;G)</bold> ELISA analysis of cytokine levels in the supernatant of CD4<sup>&#x2b;</sup> T&#x20;cells after coculturing with hsa_circ_0000652 stably expressed THP-1&#x2013;derived macrophages with or without transfection of hsa-miR-1179 (n &#x3d; 3). Data are presented as mean&#x20;&#xb1; SD. ns: <italic>p</italic>&#x20;&#x2265; 0.05; &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05; &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01; &#x2a;&#x2a;&#x2a;<italic>p &#x3c;</italic> 0.001. Each experiment was performed at least in triplicate.</p>
</caption>
<graphic xlink:href="fcell-09-737599-g006.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>Nowadays, patients with AS are still disturbed with misdiagnosis and mistreatment due to the lack of understanding of pathogenesis (<xref ref-type="bibr" rid="B29">Sieper et&#x20;al., 2015</xref>; <xref ref-type="bibr" rid="B1">Brown et&#x20;al., 2016</xref>). Emerging data show that non-coding RNAs (ncRNAs) including circRNA and miRNA, play important roles as biomarkers and regulatory factors in many rheumatic diseases (<xref ref-type="bibr" rid="B17">Li B. et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B2">Chen et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B8">Guo et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B38">Zhou et&#x20;al., 2019</xref>). It has been previously reported that some circRNAs were differentially expressed in spinal ligament tissues of patients with AS (<xref ref-type="bibr" rid="B13">Kou et&#x20;al., 2020</xref>). However, the expression profiles and functions of circRNAs in immune cells of AS are still beyond research. In the current study, we presented the differential expression profiles of circRNAs in PBMCs from AS patients by circRNA sequencing. Then we found that a circRNA hsa_circ_0000652 was upregulated in AS patients and correlated with multiple indexes of disease activity, indicating its potential to be a novel biomarker and therapeutic target. Gain-of-function and loss-of-function assays showed that hsa_circ_0000652 promoted macrophage-induced inflammation. Besides, hsa_circ_0000652 upregulated OX40L by sponging hsa-miR-1179 and aggravated the interaction between macrophages and CD4<sup>&#x2b;</sup> T&#x20;cells. These findings uncovered the characteristics and pro-inflammatory functions of hsa_circ_0000652 and OX40L in&#x20;AS.</p>
<p>Mounting studies show that antigen processing cells (APCs) are deeply involved in the pathogenesis of AS (<xref ref-type="bibr" rid="B30">Smith, 2015</xref>; <xref ref-type="bibr" rid="B26">Ranganathan et&#x20;al., 2017b</xref>; <xref ref-type="bibr" rid="B21">Menegatti et&#x20;al., 2020</xref>). Among APCs, macrophages are key pro-inflammatory cells in many rheumatic diseases and participate in osteoclastogenesis (<xref ref-type="bibr" rid="B10">Horwood, 2016</xref>; <xref ref-type="bibr" rid="B25">Ranganathan et&#x20;al., 2017a</xref>). However, the roles of AS-associated circRNAs in the activation of macrophages remain poorly understood. Our current study demonstrated that the cell ratio of CD3<sup>&#x2212;</sup>CD14<sup>&#x2b;</sup> cells was greater in AS patients, indicating that abnormal activated monocyte macrophage may be involved in the inflammation of AS. Meanwhile, hsa_circ_0000652 significantly promoted proliferation and cytokine production and inhibited the apoptosis of activated macrophages. These data suggested that hsa_circ_0000652 acted as a pro-inflammatory regulator in the proliferation and cytokine secretion in AS-associated macrophages.</p>
<p>In many biological processes, circRNAs are basically functional in acting as sponges in ceRNA, regulating RNA-binding proteins and DNA transcription or RNA translation, and being translated into polypeptides (<xref ref-type="bibr" rid="B19">Li X. et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B14">Kristensen et&#x20;al., 2019</xref>; <xref ref-type="bibr" rid="B16">Lei et&#x20;al., 2020</xref>). In the current study, we found that hsa_circ_0000652 bound with hsa-miR-1179, while hsa-miR-1179 bound with the 3&#x2032;-UTR regions of OX40L. Through the ceRNA network, hsa_circ_0000652 positively regulated OX40L expression, which was restored by hsa-miR-1179. These data implicated that hsa_circ_0000652 upregulated the expression of OX40L by sponging hsa-miR-1179.</p>
<p>OX40L along with its receptor, OX40, are known as co-stimulatory molecules and have great effects on T-cell activation and cytokine production <italic>via</italic> the interaction with APCs(<xref ref-type="bibr" rid="B5">Croft, 2009</xref>; <xref ref-type="bibr" rid="B3">2010</xref>). Previous studies found that OX40/OX40L is correlated with multiple rheumatic diseases and has the potential to be therapeutic targets (<xref ref-type="bibr" rid="B15">Laustsen et&#x20;al., 2014</xref>; <xref ref-type="bibr" rid="B11">Jacquemin et&#x20;al., 2018</xref>; <xref ref-type="bibr" rid="B6">Fu et&#x20;al., 2020</xref>). Yet, the functions of OX40/OX40L in AS have not been investigated. Our current study illustrated that OX40L was mainly expressed on CD3<sup>&#x2212;</sup>CD14<sup>&#x2b;</sup> cells and OX40 was mainly located on CD4<sup>&#x2b;</sup> T&#x20;cells in AS. As macrophages could be derived from CD3<sup>&#x2212;</sup>CD14<sup>&#x2b;</sup> cells, we speculated that OX40L expression in macrophages could be regulated by hsa_circ_0000652/hsa-miR-1179. Using the macrophage&#x2014;T-cell coculture system, we discovered that hsa_circ_0000652 could enhance the interaction between macrophages and T&#x20;cells by regulating OX40/OX40L. These results indicated that hsa_circ_0000652&#x2013;regulated OX40/OX40L may participate in the inflammatory process in AS pathogenesis.</p>
<p>Collectively, our findings revealed that hsa_circ_0000652 was upregulated in AS patients and aggravated the inflammation through activating macrophages and enhancing OX40/OX40L interaction by sponging hsa-miR-1179 (<xref ref-type="fig" rid="F7">Figure 7</xref>). Upregulated OX40L on macrophages could further interact with OX40 on CD4<sup>&#x2b;</sup> T&#x20;cells and reinforce inflammation. Unfortunately, due to the lack of a robust mouse model that perfectly mimics the pathogenesis of AS, <italic>in vivo</italic> analysis of hsa_circ_0000652 and OX40/OX40L could not be conducted in the current study. In conclusion, this study may illuminate the novel functions of hsa_circ_0000652 in the pathogenesis of AS and imply that targeting the hsa_circ_0000652/hsa-miR-1179/OX40L axis may be a promising therapeutic strategy for AS treatment.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Hsa_circ_0000652 serves as a pro-inflammatory factor in macrophage activation and an enhancer of OX40/OX40L interaction between macrophages and CD4<sup>&#x2b;</sup> T&#x20;cells.</p>
</caption>
<graphic xlink:href="fcell-09-737599-g007.tif"/>
</fig>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The data presented in the study are deposited in the NCBI Gene Expression Omnibus repository, accession number: GSE178408. Further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s6">
<title>Ethic Statement</title>
<p>The studies involving human participants were reviewed and approved by the Medical Ethics Committee of NanFang Hospital of Southern Medical University. The patients/participants provided their written informed consent to participate in this&#x20;study.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>MS, JG, and TY contributed to <italic>in&#x20;vitro</italic> assays, statistical analysis, manuscript writing, and figure assembling; JX, CZ, EB, and ZS were collaboratively involved in the study design and review of the manuscript; TA, XW, and WJ collected clinical samples and conducted assays related to clinical samples; TW and ZC contributed to the preparation of antibodies and reagents. JX and CZ acted as co-corresponding authors. All authors have reviewed and approved this manuscript for publication.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This study was supported by grants from the President Foundation of NanFang Hospital, Southern Medical University (Grant No. 2020C010), the Clinical Research Startup Program of Southern Medical University by the High-level University Construction Funding of Guangdong Provincial Department of Education (Grant No. LC2019ZD022), and the National Natural Science Foundation of China (Grant No. 81872557). Clinical Research Program of Nanfang Hospital, Southern Medical University (grant No. 2018CR001 and 2020CR028).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s10">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fcell.2021.737599/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fcell.2021.737599/full&#x23;supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table1.DOCX" id="SM1" mimetype="application/DOCX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table2.DOCX" id="SM2" mimetype="application/DOCX" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Kenna</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wordsworth</surname>
<given-names>B. P.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Genetics of Ankylosing Spondylitis-Insights into Pathogenesis</article-title>. <source>Nat. Rev. Rheumatol.</source> <volume>12</volume> (<issue>2</issue>), <fpage>81</fpage>&#x2013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1038/nrrheum.2015.133</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Circular RNAs in Immune Responses and Immune Diseases</article-title>. <source>Theranostics</source> <volume>9</volume> (<issue>2</issue>), <fpage>588</fpage>&#x2013;<lpage>607</lpage>. <pub-id pub-id-type="doi">10.7150/thno.29678</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Croft</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Control of Immunity by the TNFR-Related Molecule OX40 (CD134)</article-title>. <source>Annu. Rev. Immunol.</source> <volume>28</volume>, <fpage>57</fpage>&#x2013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-030409-101243</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Croft</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>R. M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Beyond TNF: TNF Superfamily Cytokines as Targets for the Treatment of Rheumatic Diseases</article-title>. <source>Nat. Rev. Rheumatol.</source> <volume>13</volume> (<issue>4</issue>), <fpage>217</fpage>&#x2013;<lpage>233</lpage>. <pub-id pub-id-type="doi">10.1038/nrrheum.2017.22</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Croft</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>The Role of TNF Superfamily Members in T-Cell Function and Diseases</article-title>. <source>Nat. Rev. Immunol.</source> <volume>9</volume> (<issue>4</issue>), <fpage>271</fpage>&#x2013;<lpage>285</lpage>. <pub-id pub-id-type="doi">10.1038/nri2526</pub-id> </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Therapeutic Strategies for the Costimulatory Molecule OX40 in T-Cell-Mediated Immunity</article-title>. <source>Acta Pharmaceutica Sinica B</source> <volume>10</volume> (<issue>3</issue>), <fpage>414</fpage>&#x2013;<lpage>433</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2019.08.010</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guerriero</surname>
<given-names>J.&#x20;L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Macrophages</article-title>. <source>Int. Rev. Cell Mol Biol</source> <volume>342</volume>, <fpage>73</fpage>&#x2013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/bs.ircmb.2018.07.001</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Hsa_circ_0000479 as a Novel Diagnostic Biomarker of Systemic Lupus Erythematosus</article-title>. <source>Front. Immunol.</source> <volume>10</volume>, <fpage>2281</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.02281</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Aberrant Expressions of Co-stimulatory and Co-inhibitory Molecules in Autoimmune Diseases</article-title>. <source>Front. Immunol.</source> <volume>10</volume>, <fpage>261</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2019.00261</pub-id> </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horwood</surname>
<given-names>N. J.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Macrophage Polarization and Bone Formation: A Review</article-title>. <source>Clinic Rev. Allerg Immunol.</source> <volume>51</volume> (<issue>1</issue>), <fpage>79</fpage>&#x2013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1007/s12016-015-8519-2</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacquemin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Augusto</surname>
<given-names>J.-F.</given-names>
</name>
<name>
<surname>Scherlinger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gensous</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Forcade</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Douchet</surname>
<given-names>I.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>OX40L/OX40 axis Impairs Follicular and Natural Treg Function in Human SLE</article-title>. <source>JCI Insight</source> <volume>3</volume> (<issue>24</issue>). <pub-id pub-id-type="doi">10.1172/jci.insight.122167</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kidd</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Walters</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>J.&#x20;L.</given-names>
</name>
<name>
<surname>Cawley</surname>
<given-names>M. I.</given-names>
</name>
</person-group> (<year>1989</year>). <article-title>Immunohistological Features of Synovitis in Ankylosing Spondylitis: a Comparison with Rheumatoid Arthritis</article-title>. <source>Ann. Rheum. Dis.</source> <volume>48</volume> (<issue>2</issue>), <fpage>92</fpage>&#x2013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1136/ard.48.2.92</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Profiling and Bioinformatics Analysis of Differentially Expressed circRNAs in Spinal Ligament Tissues of Patients with Ankylosing Spondylitis</article-title>. <source>Biomed. Res. Int.</source> <volume>2020</volume>, <fpage>1</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1155/2020/7165893</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kristensen</surname>
<given-names>L. S.</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Stagsted</surname>
<given-names>L. V. W.</given-names>
</name>
<name>
<surname>Ebbesen</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>T. B.</given-names>
</name>
<name>
<surname>Kjems</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>The Biogenesis, Biology and Characterization of Circular RNAs</article-title>. <source>Nat. Rev. Genet.</source> <volume>20</volume> (<issue>11</issue>), <fpage>675</fpage>&#x2013;<lpage>691</lpage>. <pub-id pub-id-type="doi">10.1038/s41576-019-0158-7</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laustsen</surname>
<given-names>J.&#x20;K.</given-names>
</name>
<name>
<surname>Rasmussen</surname>
<given-names>T. K.</given-names>
</name>
<name>
<surname>Stengaard-Pedersen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>H&#xf8;rslev-Petersen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hetland</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>&#xd8;stergaard</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Soluble OX40L Is Associated with Presence of Autoantibodies in Early Rheumatoid Arthritis</article-title>. <source>Arthritis Res. Ther.</source> <volume>16</volume> (<issue>5</issue>), <fpage>474</fpage>. <pub-id pub-id-type="doi">10.1186/s13075-014-0474-4</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lei</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ning</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Translation and Functional Roles of Circular RNAs in Human Cancer</article-title>. <source>Mol. Cancer</source> <volume>19</volume> (<issue>1</issue>), <fpage>30</fpage>. <pub-id pub-id-type="doi">10.1186/s12943-020-1135-7</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xue</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018a</year>). <article-title>Hsa_circ_0001859 Regulates ATF2 Expression by Functioning as an MiR-204/211 Sponge in Human Rheumatoid Arthritis</article-title>. <source>J.&#x20;Immunol. Res.</source> <volume>2018</volume>, <fpage>1</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1155/2018/9412387</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>L.-J.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Z.-W.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>S.-S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.-Z.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.-Z.</given-names>
</name>
<etal/>
</person-group> (<year>2018b</year>). <article-title>Circular RNA Expression Profile and Potential Function of Hsa_circ_0045272 in Systemic Lupus Erythematosus</article-title>. <source>Immunology</source> <volume>155</volume> (<issue>1</issue>), <fpage>137</fpage>&#x2013;<lpage>149</lpage>. <pub-id pub-id-type="doi">10.1111/imm.12940</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.-L.</given-names>
</name>
</person-group> (<year>2018c</year>). <article-title>The Biogenesis, Functions, and Challenges of Circular RNAs</article-title>. <source>Mol. Cell</source> <volume>71</volume> (<issue>3</issue>), <fpage>428</fpage>&#x2013;<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2018.06.034</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Memczak</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jens</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Elefsinioti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Torti</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Krueger</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rybak</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Circular RNAs Are a Large Class of Animal RNAs with Regulatory Potency</article-title>. <source>Nature</source> <volume>495</volume> (<issue>7441</issue>), <fpage>333</fpage>&#x2013;<lpage>338</lpage>. <pub-id pub-id-type="doi">10.1038/nature11928</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menegatti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Guillemot</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Latis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Yahia-Cherbal</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mitterm&#xfc;ller</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rouilly</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Immune Response Profiling of Patients with Spondyloarthritis Reveals Signalling Networks Mediating TNF-Blocker Function <italic>In Vivo</italic>
</article-title>. <source>Ann. Rheum. Dis.</source> <volume>80</volume>, <fpage>475</fpage>&#x2013;<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2020-218304</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morel</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Immunometabolism in Systemic Lupus Erythematosus</article-title>. <source>Nat. Rev. Rheumatol.</source> <volume>13</volume> (<issue>5</issue>), <fpage>280</fpage>&#x2013;<lpage>290</lpage>. <pub-id pub-id-type="doi">10.1038/nrrheum.2017.43</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>NF-&#x3ba;B: Roles and Regulation in Different CD4&#x2b;T-Cell Subsets</article-title>. <source>Immunol. Rev.</source> <volume>252</volume> (<issue>1</issue>), <fpage>41</fpage>&#x2013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12033</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pasman</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Been</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Garcia-Blanco</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Exon Circularization in Mammalian Nuclear Extracts</article-title>. <source>RNA</source> <volume>2</volume> (<issue>6</issue>), <fpage>603</fpage>&#x2013;<lpage>610</lpage>. <comment>PMID: 8718689</comment> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranganathan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ciccia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sari</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Guggino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Muralitharan</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2017a</year>). <article-title>Macrophage Migration Inhibitory Factor Induces Inflammation and Predicts Spinal Progression in Ankylosing Spondylitis</article-title>. <source>Arthritis Rheumatol.</source> <volume>69</volume> (<issue>9</issue>), <fpage>1796</fpage>&#x2013;<lpage>1806</lpage>. <pub-id pub-id-type="doi">10.1002/art.40175</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ranganathan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Gracey</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Inman</surname>
<given-names>R. D.</given-names>
</name>
<name>
<surname>Haroon</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2017b</year>). <article-title>Pathogenesis of Ankylosing Spondylitis - Recent Advances and Future Directions</article-title>. <source>Nat. Rev. Rheumatol.</source> <volume>13</volume> (<issue>6</issue>), <fpage>359</fpage>&#x2013;<lpage>367</lpage>. <pub-id pub-id-type="doi">10.1038/nrrheum.2017.56</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapouri&#x2010;Moghaddam</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mohammadian</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vazini</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Taghadosi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Esmaeili</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Mardani</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Macrophage Plasticity, Polarization, and Function in Health and Disease</article-title>. <source>J.&#x20;Cell Physiol</source> <volume>233</volume> (<issue>9</issue>), <fpage>6425</fpage>&#x2013;<lpage>6440</lpage>. <pub-id pub-id-type="doi">10.1002/jcp.26429</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>CircSERPINE2 Protects against Osteoarthritis by Targeting miR-1271 and ETS-Related Gene</article-title>. <source>Ann. Rheum. Dis.</source> <volume>78</volume> (<issue>6</issue>), <fpage>826</fpage>&#x2013;<lpage>836</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2018-214786</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sieper</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dougados</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Baeten</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Axial Spondyloarthritis</article-title>. <source>Nat. Rev. Dis. Primers</source> <volume>1</volume>, <fpage>15013</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2015.13</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>J.&#x20;A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Update on Ankylosing Spondylitis: Current Concepts in Pathogenesis</article-title>. <source>Curr. Allergy Asthma Rep.</source> <volume>15</volume> (<issue>1</issue>), <fpage>489</fpage>. <pub-id pub-id-type="doi">10.1007/s11882-014-0489-6</pub-id> </citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Salek-Ardakani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Van Parijs</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Croft</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>The Costimulation-Regulated Duration of PKB Activation Controls T&#x20;Cell Longevity</article-title>. <source>Nat. Immunol.</source> <volume>5</volume> (<issue>2</issue>), <fpage>150</fpage>&#x2013;<lpage>158</lpage>. <pub-id pub-id-type="doi">10.1038/ni1030</pub-id> </citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tardito</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Martinelli</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Soldano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Paolino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pacini</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Patane</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Macrophage M1/M2 Polarization and Rheumatoid Arthritis: A Systematic Review</article-title>. <source>Autoimmun. Rev.</source> <volume>18</volume> (<issue>11</issue>), <fpage>102397</fpage>. <pub-id pub-id-type="doi">10.1016/j.autrev.2019.102397</pub-id> </citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taurog</surname>
<given-names>J.&#x20;D.</given-names>
</name>
<name>
<surname>Chhabra</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Colbert</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Ankylosing Spondylitis and Axial Spondyloarthritis</article-title>. <source>N. Engl. J.&#x20;Med.</source> <volume>374</volume> (<issue>26</issue>), <fpage>2563</fpage>&#x2013;<lpage>2574</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra1406182</pub-id> </citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ward</surname>
<given-names>M. M.</given-names>
</name>
<name>
<surname>Deodhar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gensler</surname>
<given-names>L. S.</given-names>
</name>
<name>
<surname>Dubreuil</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>M. A.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis</article-title>. <source>Arthritis Rheumatol.</source> <volume>71</volume> (<issue>10</issue>), <fpage>1599</fpage>&#x2013;<lpage>1613</lpage>. <pub-id pub-id-type="doi">10.1002/art.41042</pub-id> </citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Watad</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rowe</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>L. K.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Normal Human Enthesis Harbours Conventional CD4&#x2b; and CD8&#x2b; T&#x20;Cells with Regulatory Features and Inducible IL-17A and TNF Expression</article-title>. <source>Ann. Rheum. Dis.</source> <volume>79</volume> (<issue>8</issue>), <fpage>1044</fpage>&#x2013;<lpage>1054</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2020-217309</pub-id> </citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Webb</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Hirschfield</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Lane</surname>
<given-names>P. J.&#x20;L.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>OX40, OX40L and Autoimmunity: a Comprehensive Review</article-title>. <source>Clinic Rev. Allerg Immunol.</source> <volume>50</volume> (<issue>3</issue>), <fpage>312</fpage>&#x2013;<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1007/s12016-015-8498-3</pub-id> </citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>CircRNA_09505 Aggravates Inflammation and Joint Damage in Collagen-Induced Arthritis Mice via miR-6089/akt1/nf-&#x39a;b axis</article-title>. <source>Cell Death Dis</source> <volume>11</volume> (<issue>10</issue>), <fpage>833</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-020-03038-z</pub-id> </citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Roles of Circular RNAs in Immune Regulation and Autoimmune Diseases</article-title>. <source>Cell Death Dis</source> <volume>10</volume> (<issue>7</issue>), <fpage>503</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-019-1744-5</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>